DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ADVAIR DISKUS 100/50

Summary for Tradename: ADVAIR DISKUS 100/50

Patents:1
Applicants:1
NDAs:1
Suppliers: see list8
Formulation / Manufacturing:see details
drug
patent expirations by year for
 ADVAIR DISKUS 100/50

Pharmacology for Tradename: ADVAIR DISKUS 100/50

Clinical Trials for: ADVAIR DISKUS 100/50

Fall Epidemic Viral Pediatric Study
Status: Completed Condition: Asthma

Dose-Response of Salmeterol in Children
Status: Recruiting Condition: Asthma

Best African American Response to Asthma Drugs
Status: Recruiting Condition: Asthma

Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo
Status: Completed Condition: Asthma; Seasonal Allergic Rhinitis

A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS
Status: Completed Condition: Asthma

Study Of Patients With Allergic Rhinitis And Asthma
Status: Completed Condition: Asthma

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects
Status: Completed Condition: Asthma

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old
Status: Recruiting Condition: Asthma

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.
Status: Recruiting Condition: Asthma

Advair Pediatric Once-Daily
Status: Completed Condition: Asthma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp Ltd
ADVAIR DISKUS 100/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077Aug 24, 2000RXYes5,873,360*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc